ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olutasidenib

Also written as “Olutasidenib”, “Olutasidenib + TMZ” and “FT-2102 (olutasidenib)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Glioma · Glioblastoma, led by 3 companies.

Drug pageOlutasidenib: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 21, 20165 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only20 open or runningphase 2since Mar 21, 2016Mar 21, 2016none ahead
Rigel Pharmaceuticals22 open or runningphase 4since Mar 12, 2026Nov 22, 2023Apr 30, 2027phase 4 · NCT07486713
Kissei Pharmaceuticalits history only11 open or runningphase 2since May 18, 2026May 18, 2026Sep 2030phase 2 · NCT07604064

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Rigel Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named olutasidenibINNProposed as its International Nonproprietary Name in WHO's List 120 · before, FT-2102
  2. Nov 22, 2023First study: phase 2 study in GliomaFirst studyNCT06161974 · 60 planned · United States, Australia, Canada and more
  3. Mar 12, 2026Phase 4 study in Leukemia, Myeloid, AcuteNCT07486713 · 16 planned · United States

Ahead

  1. Apr 30, 2027Primary completion: phase 4 study in Leukemia, Myeloid, AcuteNCT07486713
  2. Jun 2029Primary completion: phase 2 study in GliomaNCT06161974

TargetBeta

IDH1 →read by rule
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on IDH1

ProgramCompanyFurthest phaseStudies
ivosidenibruleAgios Pharmaceuticalsphase 313
vorasidenibruleAgios Pharmaceuticalsphase 312
ranosidenibruleHUTCHMEDphase 37
safusidenibruleNuvation Biophase 36
IDH1 Inhibitor TQB3454Sino Biopharmaceuticalphase 35

Studies

All 2 Rigel Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07486713Leukemia, Myeloid, Acute · United States4RecruitingApr 30, 202716
NCT06161974Glioma · United States, Australia, Canada and more2RecruitingJun 202960

How it is read

Names in the registry

  • “Olutasidenib”, 2 entries
  • “Olutasidenib + TMZ”, 1 entry
  • “FT-2102 (olutasidenib)”, 1 entry
  • “FT-2102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.